Skip to content
value.today

Samumed: peers

Change the peers

Samumed beside the 7 companies most like it by industry, size and country: every figure with its date and source, its rank in the group and its percentile in its sector and country.

Samumed: the market cap on file is more than 60 days old or a last known value (no market-data feed for its exchange yet), so its valuation multiples and yields are shown but not ranked.

Side by side#

Every figure with its fiscal year or date and its source. Switch to each company's rank in the group, or its percentile in its sector or country. How ranks are worked out.

Samumed, UnitedHealth Group Incorporated, Eli Lilly and Company, Merck & Co., Inc., AbbVie Inc., Thermo Fisher Scientific Inc., Pfizer Inc., Abbott Laboratories side by side: each figure with its period and source, its rank among these companies and its percentile in the company's sector and country
MeasureSamumedbase
🇺🇸 US
Percentile in Healthcare
Percentile in USA
UnitedHealth Group Incorporated
UNH · 🇺🇸 US
Percentile in Healthcare
Percentile in USA
Eli Lilly and Company
LLY · 🇺🇸 US
Percentile in Healthcare
Percentile in USA
Merck & Co., Inc.
MRK · 🇺🇸 US
Percentile in Healthcare
Percentile in USA
AbbVie Inc.
ABBV · 🇺🇸 US
Percentile in Healthcare
Percentile in USA
Thermo Fisher Scientific Inc.
TMO · 🇺🇸 US
Percentile in Healthcare
Percentile in USA
Pfizer Inc.
PFE · 🇺🇸 US
Percentile in Healthcare
Percentile in USA
Abbott Laboratories
ABT · 🇺🇸 US
Percentile in Healthcare
Percentile in USA
Group median
Size
Market cap (Better neither way: ranked highest first)——$367.7 BOct 28, 2026 · Market data3rd of 7$1.20 TOct 26, 2026 · Market data1st of 7$359.8 BOct 19, 2026 · Market data4th of 7$514.0 BOct 30, 2026 · Market data2nd of 7$253.8 BOct 27, 2026 · Market data5th of 7$170.7 BOct 30, 2026 · Market data7th of 7$181.1 BOct 30, 2026 · Market data6th of 7$359.8 B7 ranked
Revenue (Better neither way: ranked highest first)——$447.6 BFY2025 · SEC1st of 7$65.2 BFY2025 · SEC2nd of 7$65.0 BFY2025 · SEC3rd of 7$61.2 BFY2025 · SEC5th of 7$44.6 BFY2025 · SEC6th of 7$62.6 BFY2025 · SEC4th of 7$44.3 BFY2025 · SEC7th of 7$62.6 B7 ranked
Net income (Higher is better)——$12.1 BFY2025 · SEC3rd of 7$20.6 BFY2025 · SEC1st of 7$18.3 BFY2025 · SEC2nd of 7$4.2 BFY2025 · SEC7th of 7$6.7 BFY2025 · SEC5th of 7$7.8 BFY2025 · SEC4th of 7$6.5 BFY2025 · SEC6th of 7$7.8 B7 ranked
Employees (Better neither way: ranked highest first)——390,000December 31, 2025 · Profile1st of 750,000December 31, 2025 · Profile7th of 775,000December 31, 2025 · Profile4th of 757,000December 31, 2025 · Profile6th of 7125,000December 31, 2025 · Profile2nd of 775,000December 31, 2025 · Profile4th of 7115,000As on Dec-2022 · Profile3rd of 775,0007 ranked
Growth
Revenue growth (Higher is better)————+11.8%FY2025 · SEC2nd of 754th66th+44.7%FY2025 · SEC1st of 782nd91st+1.3%FY2025 · SEC6th of 729th33rd+8.6%FY2025 · SEC3rd of 746th57th+3.9%FY2025 · SEC5th of 734th42nd-1.6%FY2025 · SEC7th of 722nd25th+5.7%FY2025 · SEC4th of 739th48th+5.7%7 ranked
Revenue growth, 3 years a year (Higher is better)————+11.3%FY2025 · SEC2nd of 757th73rd+31.7%FY2025 · SEC1st of 782nd92nd+3.1%FY2025 · SEC3rd of 737th45th+1.8%FY2025 · SEC4th of 732nd39th-0.3%FY2025 · SEC6th of 727th32nd-14.8%FY2025 · SEC7th of 710th6th+0.5%FY2025 · SEC5th of 728th35th+1.8%7 ranked
Earnings per share growth (Higher is better)————-14.7%FY2025 · SEC6th of 723rd25th+96.0%FY2025 · SEC1st of 787th89th+8.0%FY2025 · SEC2nd of 749th48th-1.3%FY2025 · SEC4th of 735th36th+7.3%FY2025 · SEC3rd of 748th47th-3.5%FY2025 · SEC5th of 732nd33rd-51.3%FY2025 · SEC7th of 710th9th-1.3%7 ranked
Margins and returns
Gross margin (Higher is better)————88.7%FY2025 · SEC1st of 691st96th83.0%FY2025 · SEC2nd of 684th93rd74.8%FY2025 · SEC3rd of 674th87th70.2%FY2025 · SEC5th of 669th83rd————74.3%FY2025 · SEC4th of 673rd86th56.4%FY2025 · SEC6th of 647th70th74.6%6 ranked
Operating margin (Higher is better)————4.2%FY2025 · SEC4th of 464th53rd————————24.6%FY2025 · SEC1st of 492nd90th17.4%FY2025 · SEC3rd of 485th82nd————18.2%FY2025 · SEC2nd of 486th83rd17.8%4 ranked
Net margin (Higher is better)————2.7%FY2025 · SEC7th of 765th53rd31.7%FY2025 · SEC1st of 795th95th28.1%FY2025 · SEC2nd of 793rd94th6.9%FY2025 · SEC6th of 773rd67th15.1%FY2025 · SEC3rd of 785th84th12.4%FY2025 · SEC5th of 782nd79th14.7%FY2025 · SEC4th of 785th83rd14.7%7 ranked
Free cash flow margin (Higher is better)————3.6%FY2025 · SEC6th of 659th48th————19.0%FY2025 · SEC2nd of 686th87th29.1%FY2025 · SEC1st of 696th95th14.1%FY2025 · SEC5th of 679th79th14.5%FY2025 · SEC4th of 680th80th16.7%FY2025 · SEC3rd of 683rd83rd15.6%6 ranked
Return on equity (Higher is better)————12.2%FY2025 · SEC5th of 684th71st101.2%FY2025 · SEC1st of 699th98th36.9%FY2025 · SEC2nd of 696th94th————13.0%FY2025 · SEC4th of 685th73rd8.9%FY2025 · SEC6th of 680th61st13.1%FY2025 · SEC3rd of 685th74th13.0%6 ranked
Return on invested capital (Higher is better)————11.3%FY2025 · SEC2nd of 452nd53rd————————16.0%FY2025 · SEC1st of 466th70th9.0%FY2025 · SEC4th of 435th41st————11.2%FY2025 · SEC3rd of 450th52nd11.2%4 ranked
Valuation
P/E ratio (Better neither way: ranked highest first)————23.1×price Oct 28, 2026 · Market data7th of 739th60th43.4×price Oct 26, 2026 · Market data3rd of 767th84th146.7×price Oct 19, 2026 · Market data1st of 793rd97th49.7×price Oct 30, 2026 · Market data2nd of 771st87th35.9×price Oct 27, 2026 · Market data6th of 756th79th42.3×price Oct 30, 2026 · Market data4th of 766th83rd38.5×price Oct 30, 2026 · Market data5th of 759th81st42.3×7 ranked
Price to sales (Better neither way: ranked highest first)————0.8×price Oct 28, 2026 · Market data7th of 714th25th13.9×price Oct 26, 2026 · Market data1st of 778th92nd5.3×price Oct 19, 2026 · Market data4th of 759th79th7.8×price Oct 30, 2026 · Market data2nd of 768th86th5.4×price Oct 27, 2026 · Market data3rd of 759th79th2.7×price Oct 30, 2026 · Market data6th of 741st56th3.8×price Oct 30, 2026 · Market data5th of 750th69th5.3×7 ranked
Price to book (Better neither way: ranked highest first)————3.7×price Oct 28, 2026 · Market data4th of 657th68th45.1×price Oct 26, 2026 · Market data1st of 697th98th6.8×price Oct 19, 2026 · Market data2nd of 676th83rd————4.8×price Oct 27, 2026 · Market data3rd of 665th75th2.0×price Oct 30, 2026 · Market data6th of 637th47th3.5×price Oct 30, 2026 · Market data5th of 655th66th4.2×6 ranked
Free cash flow yield (Higher is better)————4.4%price Oct 28, 2026 · Market data2nd of 684th62nd————3.4%price Oct 19, 2026 · Market data5th of 680th56th3.5%price Oct 30, 2026 · Market data4th of 681st56th2.5%price Oct 27, 2026 · Market data6th of 677th49th5.3%price Oct 30, 2026 · Market data1st of 688th68th4.1%price Oct 30, 2026 · Market data3rd of 683rd61st3.8%6 ranked
Financial strength
Debt to equity (Lower is better)————0.7×FY2025 · SEC3rd of 665th56th1.5×FY2025 · SEC6th of 686th80th0.9×FY2025 · SEC5th of 673rd64th————0.7×FY2025 · SEC4th of 666th57th0.7×FY2025 · SEC2nd of 665th55th0.3×FY2025 · SEC1st of 636th27th0.7×6 ranked
Net debt to EBITDA (Lower is better)————2.1×FY2025 · SEConly one with it53rd50th————————————————————————2.1×—
Interest cover (Higher is better)————4.7×FY2025 · SEC2nd of 285th73rd————————5.2×FY2025 · SEC1st of 286th74th————————————5.0×2 ranked
Piotroski F-score (Higher is better)——7 of 9FY2025 · SEC2nd of 67 of 9FY2025 · SEC2nd of 64 of 9FY2025 · SEC6th of 68 of 9FY2025 · SEC1st of 6——5 of 9FY2025 · SEC5th of 66 of 9FY2025 · SEC4th of 66.5 of 96 ranked
Scorecard
Scorecard (Higher is better)——19 of 30FY2025 · Scorecard3rd of 715 of 21FY2025 · Scorecard1st of 716 of 24FY2025 · Scorecard2nd of 713 of 27FY2025 · Scorecard7th of 716 of 28FY2025 · Scorecard4th of 711 of 21FY2025 · Scorecard6th of 715 of 27FY2025 · Scorecard5th of 757% passed7 ranked
Valuation checks (Higher is better)——2 of 6FY2025 · Scorecard2nd of 70 of 4FY2025 · Scorecard3rd of 70 of 6FY2025 · Scorecard3rd of 70 of 6FY2025 · Scorecard3rd of 70 of 6FY2025 · Scorecard3rd of 73 of 6FY2025 · Scorecard1st of 70 of 6FY2025 · Scorecard3rd of 70% passed7 ranked
Growth checks (Higher is better)——3 of 6FY2025 · Scorecard4th of 76 of 6FY2025 · Scorecard1st of 75 of 6FY2025 · Scorecard2nd of 72 of 6FY2025 · Scorecard6th of 74 of 6FY2025 · Scorecard3rd of 70 of 6FY2025 · Scorecard7th of 73 of 6FY2025 · Scorecard4th of 750% passed7 ranked
Profitability checks (Higher is better)——4 of 6FY2025 · Scorecard4th of 73 of 3FY2025 · Scorecard1st of 73 of 3FY2025 · Scorecard1st of 74 of 5FY2025 · Scorecard3rd of 73 of 6FY2025 · Scorecard7th of 72 of 3FY2025 · Scorecard4th of 74 of 6FY2025 · Scorecard4th of 767% passed7 ranked
Financial health checks (Higher is better)——4 of 6FY2025 · Scorecard6th of 72 of 3FY2025 · Scorecard6th of 73 of 3FY2025 · Scorecard1st of 73 of 4FY2025 · Scorecard5th of 74 of 4FY2025 · Scorecard1st of 73 of 3FY2025 · Scorecard1st of 74 of 4FY2025 · Scorecard1st of 7100% passed7 ranked
Shareholder returns checks (Higher is better)——6 of 6FY2025 · Scorecard1st of 74 of 5FY2025 · Scorecard5th of 75 of 6FY2025 · Scorecard3rd of 74 of 6FY2025 · Scorecard7th of 75 of 6FY2025 · Scorecard3rd of 73 of 3FY2025 · Scorecard1st of 74 of 5FY2025 · Scorecard5th of 783% passed7 ranked
Ownership
Held by institutions (Better neither way: ranked highest first)——85.7%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in2nd of 782.6%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in3rd of 778.2%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in5th of 774.1%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in6th of 791.1%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in1st of 766.2%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in7th of 778.5%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in4th of 778.5%7 ranked
Institutions holding (Better neither way: ranked highest first)——3,2932026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in4th of 74,6162026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in1st of 73,9602026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in3rd of 74,2722026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in2nd of 72,7962026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in7th of 72,9082026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in6th of 73,0332026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in5th of 73,2937 ranked
Institutional holding, change over the quarter (Better neither way: ranked highest first)——+5.3 pp2026-Q2 against 2026-Q1 · 13F1st of 7+1.3 pp2026-Q2 against 2026-Q1 · 13F6th of 7+2.3 pp2026-Q2 against 2026-Q1 · 13F2nd of 7+2.1 pp2026-Q2 against 2026-Q1 · 13F3rd of 7+1.6 pp2026-Q2 against 2026-Q1 · 13F4th of 7+1.6 pp2026-Q2 against 2026-Q1 · 13F5th of 7+0.9 pp2026-Q2 against 2026-Q1 · 13F7th of 7+1.6 pp7 ranked
Dividends
Dividend yield (Higher is better)————2.1%FY2025 · SEC4th of 675th51st0.5%FY2025 · SEC5th of 632nd13th2.3%FY2025 · SEC1st of 680th54th2.3%FY2025 · SEC1st of 680th54th0.3%FY2025 · SEC6th of 623rd9th————2.3%FY2025 · SEC1st of 680th54th2.2%6 ranked
Shareholder yield (Higher is better)————3.7%FY2025 · SEC2nd of 666th56th0.8%FY2025 · SEC6th of 629th19th3.7%FY2025 · SEC1st of 666th56th2.5%FY2025 · SEC4th of 653rd40th1.4%FY2025 · SEC5th of 639th27th————2.8%FY2025 · SEC3rd of 658th45th2.6%6 ranked
Dividend payout (Better neither way: ranked highest first)————65.7%FY2025 · SEC2nd of 681st73rd26.1%FY2025 · SEC5th of 644th32nd44.8%FY2025 · SEC4th of 672nd58th275.8%FY2025 · SEC1st of 698th97th9.5%FY2025 · SEC6th of 620th10th————63.1%FY2025 · SEC3rd of 680th71st53.9%6 ranked
Dividend per share (Better neither way: ranked highest first)——$8.73FY2025 · SEC1st of 7$6.23FY2025 · SEC3rd of 7$3.28FY2025 · SEC4th of 7$6.65FY2025 · SEC2nd of 7$1.72FY2025 · SEC6th of 7$1.72FY2025 · SEC6th of 7$2.40FY2025 · SEC5th of 7$3.287 ranked
Years of dividend raises (Higher is better)——15to 2025 · SEC1st of 65to 2019 · SEC5th of 615to 2025 · SEC1st of 63to 2025 · SEC6th of 68to 2025 · SEC4th of 615to 2025 · SEC1st of 6——126 ranked

Under each figure: its fiscal year, quarter or date, and its source. ↑ higher is better, ↓ lower is better, · better neither way (ranked highest first). Ranks count only the companies with the figure; percentiles place each company among all the companies of its own sector and country with the figure (ten or more needed).

Sources: SEC = SEC annual reports (10-K, 20-F, 40-F); ESEF = ESEF annual reports (European and UK listed companies); Editors = The company's annual report, entered by value.today editors; Wikidata = Wikidata, citing the annual report; Scorecard = value.today scorecard: thirty checks on the company's statements, worked out daily; 13F = SEC Form 13F holdings reports; SEC = Dividends declared per share in SEC 10-Q and 10-K filings; Profile = The company's latest reported headcount; Market data = Samumed: How market caps are worked out; UnitedHealth Group Incorporated: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Eli Lilly and Company: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Merck & Co., Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; AbbVie Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Thermo Fisher Scientific Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Pfizer Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Abbott Laboratories: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover.

Where each stands in its sector and country: Operating margin#

The dot is the company; the line runs from the 10th to the 90th percentile of all the companies of its sector (or country) with the figure, the box holds the middle half and the tick is the median. Each company's newest fiscal year; figures that divide by the market value only with a market cap at most 60 days old. How percentiles are worked out.

Operating margin: each company's figure and its percentile in its sector and its country
CompanyOperating marginIn its sectorIn its country
Samumed———
UnitedHealth Group Incorporated4.2%FY2025
64th percentile in Healthcaremedian -7.7%, 674 companies
53rd percentile in USAmedian 3.5%, 2,594 companies
Eli Lilly and Company———
Merck & Co., Inc.———
AbbVie Inc.24.6%FY2025
92nd percentile in Healthcaremedian -7.7%, 674 companies
90th percentile in USAmedian 3.5%, 2,594 companies
Thermo Fisher Scientific Inc.17.4%FY2025
85th percentile in Healthcaremedian -7.7%, 674 companies
82nd percentile in USAmedian 3.5%, 2,594 companies
Pfizer Inc.———
Abbott Laboratories18.2%FY2025
86th percentile in Healthcaremedian -7.7%, 674 companies
83rd percentile in USAmedian 3.5%, 2,594 companies

Revenue by fiscal year, and the rank in the group#

Revenue of the fiscal year. US dollars at each year's exchange rate; fiscal years as each company names them. Ranks: 1st is the highest (better neither way).

Revenue

$0 M$111.9 B$223.8 B$335.7 B$447.6 B200820102012201420162018202020222024UnitedHealth Group Incorporated $447.6 BEli Lilly and Company $65.2 BMerck & Co., Inc. $65.0 BAbbVie Inc. $61.2 BThermo Fisher Scientific Inc. $44.6 BPfizer Inc. $62.6 BAbbott Laboratories $44.3 B

Rank in the group

1st2nd3rd4th5th6th7th201120122013201420152016201720182019202020212022202320242025UnitedHealth Group Incorporated: 1st of 7 in 2011UnitedHealth Group Incorporated: 1st of 7 in 2012UnitedHealth Group Incorporated: 1st of 7 in 2013UnitedHealth Group Incorporated: 1st of 7 in 2014UnitedHealth Group Incorporated: 1st of 7 in 2015UnitedHealth Group Incorporated: 1st of 7 in 2016UnitedHealth Group Incorporated: 1st of 7 in 2017UnitedHealth Group Incorporated: 1st of 7 in 2018UnitedHealth Group Incorporated: 1st of 7 in 2019UnitedHealth Group Incorporated: 1st of 7 in 2020UnitedHealth Group Incorporated: 1st of 7 in 2021UnitedHealth Group Incorporated: 1st of 7 in 2022UnitedHealth Group Incorporated: 1st of 7 in 2023UnitedHealth Group Incorporated: 1st of 7 in 2024UnitedHealth Group Incorporated: 1st of 7 in 2025UnitedHealth Group IncorpoEli Lilly and Company: 4th of 7 in 2011Eli Lilly and Company: 4th of 7 in 2012Eli Lilly and Company: 4th of 7 in 2013Eli Lilly and Company: 6th of 7 in 2014Eli Lilly and Company: 6th of 7 in 2015Eli Lilly and Company: 5th of 7 in 2016Eli Lilly and Company: 7th of 7 in 2017Eli Lilly and Company: 7th of 7 in 2018Eli Lilly and Company: 7th of 7 in 2019Eli Lilly and Company: 7th of 7 in 2020Eli Lilly and Company: 7th of 7 in 2021Eli Lilly and Company: 7th of 7 in 2022Eli Lilly and Company: 7th of 7 in 2023Eli Lilly and Company: 5th of 7 in 2024Eli Lilly and Company: 2nd of 7 in 2025Eli Lilly and CompanyMerck & Co., Inc.: 3rd of 7 in 2011Merck & Co., Inc.: 3rd of 7 in 2012Merck & Co., Inc.: 3rd of 7 in 2013Merck & Co., Inc.: 3rd of 7 in 2014Merck & Co., Inc.: 3rd of 7 in 2015Merck & Co., Inc.: 3rd of 7 in 2016Merck & Co., Inc.: 3rd of 7 in 2017Merck & Co., Inc.: 2nd of 7 in 2018Merck & Co., Inc.: 3rd of 7 in 2019Merck & Co., Inc.: 4th of 7 in 2020Merck & Co., Inc.: 4th of 7 in 2021Merck & Co., Inc.: 3rd of 7 in 2022Merck & Co., Inc.: 2nd of 7 in 2023Merck & Co., Inc.: 2nd of 7 in 2024Merck & Co., Inc.: 3rd of 7 in 2025Merck & Co., Inc.AbbVie Inc.: 6th of 7 in 2011AbbVie Inc.: 6th of 7 in 2012AbbVie Inc.: 6th of 7 in 2013AbbVie Inc.: 5th of 7 in 2014AbbVie Inc.: 4th of 7 in 2015AbbVie Inc.: 4th of 7 in 2016AbbVie Inc.: 4th of 7 in 2017AbbVie Inc.: 4th of 7 in 2018AbbVie Inc.: 4th of 7 in 2019AbbVie Inc.: 2nd of 7 in 2020AbbVie Inc.: 3rd of 7 in 2021AbbVie Inc.: 4th of 7 in 2022AbbVie Inc.: 4th of 7 in 2023AbbVie Inc.: 4th of 7 in 2024AbbVie Inc.: 5th of 7 in 2025AbbVie Inc.Thermo Fisher Scientific Inc.: 7th of 7 in 2011Thermo Fisher Scientific Inc.: 7th of 7 in 2012Thermo Fisher Scientific Inc.: 7th of 7 in 2013Thermo Fisher Scientific Inc.: 7th of 7 in 2014Thermo Fisher Scientific Inc.: 7th of 7 in 2015Thermo Fisher Scientific Inc.: 7th of 7 in 2016Thermo Fisher Scientific Inc.: 6th of 7 in 2017Thermo Fisher Scientific Inc.: 6th of 7 in 2018Thermo Fisher Scientific Inc.: 6th of 7 in 2019Thermo Fisher Scientific Inc.: 6th of 7 in 2020Thermo Fisher Scientific Inc.: 6th of 7 in 2021Thermo Fisher Scientific Inc.: 5th of 7 in 2022Thermo Fisher Scientific Inc.: 5th of 7 in 2023Thermo Fisher Scientific Inc.: 6th of 7 in 2024Thermo Fisher Scientific Inc.: 6th of 7 in 2025Thermo Fisher Scientific IPfizer Inc.: 2nd of 7 in 2011Pfizer Inc.: 2nd of 7 in 2012Pfizer Inc.: 2nd of 7 in 2013Pfizer Inc.: 2nd of 7 in 2014Pfizer Inc.: 2nd of 7 in 2015Pfizer Inc.: 2nd of 7 in 2016Pfizer Inc.: 2nd of 7 in 2017Pfizer Inc.: 3rd of 7 in 2018Pfizer Inc.: 2nd of 7 in 2019Pfizer Inc.: 3rd of 7 in 2020Pfizer Inc.: 2nd of 7 in 2021Pfizer Inc.: 2nd of 7 in 2022Pfizer Inc.: 3rd of 7 in 2023Pfizer Inc.: 3rd of 7 in 2024Pfizer Inc.: 4th of 7 in 2025Pfizer Inc.Abbott Laboratories: 5th of 7 in 2011Abbott Laboratories: 5th of 7 in 2012Abbott Laboratories: 5th of 7 in 2013Abbott Laboratories: 4th of 7 in 2014Abbott Laboratories: 5th of 7 in 2015Abbott Laboratories: 6th of 7 in 2016Abbott Laboratories: 5th of 7 in 2017Abbott Laboratories: 5th of 7 in 2018Abbott Laboratories: 5th of 7 in 2019Abbott Laboratories: 5th of 7 in 2020Abbott Laboratories: 5th of 7 in 2021Abbott Laboratories: 6th of 7 in 2022Abbott Laboratories: 6th of 7 in 2023Abbott Laboratories: 7th of 7 in 2024Abbott Laboratories: 7th of 7 in 2025Abbott Laboratories
Revenue by fiscal year with each company's rank in the group and the source of each figure
Fiscal yearSamumedUnitedHealth Group IncorporatedEli Lilly and CompanyMerck & Co., Inc.AbbVie Inc.Thermo Fisher Scientific Inc.Pfizer Inc.Abbott Laboratories
2025—$447.6 BSEC1st$65.2 BSEC2nd$65.0 BSEC3rd$61.2 BSEC5th$44.6 BSEC6th$62.6 BSEC4th$44.3 BSEC7th
2024—$400.3 BSEC1st$45.0 BSEC5th$64.2 BSEC2nd$56.3 BSEC4th$42.9 BSEC6th$63.6 BSEC3rd$42.0 BSEC7th
2023—$371.6 BSEC1st$34.1 BSEC7th$60.1 BSEC2nd$54.3 BSEC4th$42.9 BSEC5th$59.6 BSEC3rd$40.1 BSEC6th
2022—$324.2 BSEC1st$28.5 BSEC7th$59.3 BSEC3rd$58.1 BSEC4th$44.9 BSEC5th$101.2 BSEC2nd$43.7 BSEC6th
2021—$287.6 BSEC1st$28.3 BSEC7th$48.7 BSEC4th$56.2 BSEC3rd$39.2 BSEC6th$81.3 BSEC2nd$43.1 BSEC5th
2020—$257.1 BSEC1st$24.5 BSEC7th$41.5 BSEC4th$45.8 BSEC2nd$32.2 BSEC6th$41.7 BSEC3rd$34.6 BSEC5th
2019—$242.2 BSEC1st$22.3 BSEC7th$39.1 BSEC3rd$33.3 BSEC4th$25.5 BSEC6th$40.9 BSEC2nd$31.9 BSEC5th
2018—$226.2 BSEC1st$21.5 BSEC7th$42.3 BSEC2nd$32.8 BSEC4th$24.4 BSEC6th$40.8 BSEC3rd$30.6 BSEC5th
2017—$201.2 BSEC1st$20.0 BSEC7th$40.1 BSEC3rd$28.2 BSEC4th$20.9 BSEC6th$52.5 BSEC2nd$27.4 BSEC5th
2016—$184.8 BSEC1st$21.2 BSEC5th$39.8 BSEC3rd$25.6 BSEC4th$18.3 BSEC7th$52.8 BSEC2nd$20.9 BSEC6th
2015—$157.1 BSEC1st$20.0 BSEC6th$39.5 BSEC3rd$22.9 BSEC4th$17.0 BSEC7th$48.9 BSEC2nd$20.4 BSEC5th
2014—$130.5 BSEC1st$19.6 BSEC6th$42.2 BSEC3rd$20.0 BSEC5th$16.9 BSEC7th$49.6 BSEC2nd$20.2 BSEC4th

Sources: SEC = SEC annual reports (10-K, 20-F, 40-F); ESEF = ESEF annual reports (European and UK listed companies); Ed. = The company's annual report, entered by value.today editors; WD = Wikidata, citing the annual report; Cap = value.today market caps (the last of each calendar year). The small ordinal is the rank in the group that year. Hover a figure for its fiscal year end.

Suggested peers of Samumed#

Companies of the same industry first, then the same sector, within a hundred times its size (market cap), scored out of 100 for industry, size, country and figures on file. How peers are suggested.

  • UnitedHealth Group IncorporatedUNH · 🇺🇸 USA
    Same sector: Healthcare (Healthcare Plans) · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $367.7 B (Oct 28, 2026) · revenue $447.6 B (year to December 2025)
    45 of 100 (industry or sector 25 + country 15 + figures on file 5)
    In the group
  • Eli Lilly and CompanyLLY · 🇺🇸 USA
    Same sector: Healthcare (Pharmaceutical) · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $1.20 T (Oct 26, 2026) · revenue $65.2 B (year to December 2025)
    45 of 100 (industry or sector 25 + country 15 + figures on file 5)
    In the group
  • Merck & Co., Inc.MRK · 🇺🇸 USA
    Same sector: Healthcare (Pharmaceutical) · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $359.8 B (Oct 19, 2026) · revenue $65.0 B (year to December 2025)
    45 of 100 (industry or sector 25 + country 15 + figures on file 5)
    In the group
  • AbbVie Inc.ABBV · 🇺🇸 USA
    Same sector: Healthcare (Pharmaceutical) · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $514.0 B (Oct 30, 2026) · revenue $61.2 B (year to December 2025)
    45 of 100 (industry or sector 25 + country 15 + figures on file 5)
    In the group
  • Thermo Fisher Scientific Inc.TMO · 🇺🇸 USA
    Same sector: Healthcare (Diagnostics and Research) · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $253.8 B (Oct 27, 2026) · revenue $44.6 B (year to December 2025)
    45 of 100 (industry or sector 25 + country 15 + figures on file 5)
    In the group
  • Pfizer Inc.PFE · 🇺🇸 USA
    Same sector: Healthcare (Pharmaceutical) · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $170.7 B (Oct 30, 2026) · revenue $62.6 B (year to December 2025)
    45 of 100 (industry or sector 25 + country 15 + figures on file 5)
    In the group
  • Abbott LaboratoriesABT · 🇺🇸 USA
    Same sector: Healthcare (Medical Devices) · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $181.1 B (Oct 30, 2026) · revenue $44.3 B (year to December 2025)
    45 of 100 (industry or sector 25 + country 15 + figures on file 5)
    In the group
  • Danaher CorporationDHR · 🇺🇸 USA
    Same sector: Healthcare (Diagnostics and Research) · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $166.7 B (Oct 30, 2026) · revenue $24.6 B (year to December 2025)
    45 of 100 (industry or sector 25 + country 15 + figures on file 5)
    + Add
  • Bristol-Myers Squibb CompanyBMY · 🇺🇸 USA
    Same sector: Healthcare (Pharmaceutical) · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $125.5 B (Oct 30, 2026) · revenue $48.2 B (year to December 2025)
    45 of 100 (industry or sector 25 + country 15 + figures on file 5)
    + Add
  • Amgen Inc.AMGN · 🇺🇸 USA
    Same sector: Healthcare (Pharmaceutical) · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $249.2 B (Oct 30, 2026) · revenue $36.8 B (year to December 2025)
    45 of 100 (industry or sector 25 + country 15 + figures on file 5)
    + Add
  • Medtronic plcMDT · 🇺🇸 USA
    Same sector: Healthcare (Medical Devices) · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $121.2 B (Oct 29, 2026) · revenue $36.4 B (year to April 2026)
    45 of 100 (industry or sector 25 + country 15 + figures on file 5)
    + Add
  • Intuitive Surgical, Inc.ISRG · 🇺🇸 USA
    Same sector: Healthcare (Medical Instruments) · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $155.6 B (Oct 30, 2026) · revenue $10.1 B (year to December 2025)
    45 of 100 (industry or sector 25 + country 15 + figures on file 5)
    + Add

Any figure over the years, other peers or a saved group: open this group in the peer workspace.